Sugi Predict

Sugi Predict / Compounds / SCHEMBL4357578

SCHEMBL4357578

SCHEMBL4357578

O=C(Cc1c[nH]c2ccccc12)Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 8/20 0.49
▸ CCKBR P32239 1/20 0.43
▸ MAPT P10636 4/20 0.42
▸ PKM P14618 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ MEN1 O00255 2/20 0.40
▸ STAT3 P40763 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ STK4 Q13043 1/20 0.39
▸ STK3 Q13188 1/20 0.39
▸ STK26 Q9P289 1/20 0.39
▸ STK24 Q9Y6E0 1/20 0.39
▸ JAK2 O60674 5/20 0.39
▸ JAK1 P23458 5/20 0.39
▸ TYK2 P29597 5/20 0.39
▸ JAK3 P52333 5/20 0.39
▸ CCNE1 P24864 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4364299 0.95 ALK (0.45) ALKCCKBRMAPTPKMALDH1A1
SCHEMBL1075006 0.86 ALK (0.49) ALKSTK4STK3STK26STK24
SCHEMBL4361548 0.86 ALK (0.55) ALKMEN1KMT2ASTK4STK3
SCHEMBL1072668 0.84 ALK (0.53) ALKMAPTALDH1A1HTTSTK4
SCHEMBL1076439 0.83 ALK (0.58) ALKSTK4STK3STK26STK24
SCHEMBL4357395 0.83 ALK (0.57) ALKSTK4STK3STK26STK24
SCHEMBL1075387 0.83 ALK (0.54) ALKSTK4STK3STK26STK24
SCHEMBL1075560 0.83 ALK (0.53) ALKSTK4STK3STK26STK24
SCHEMBL4366266 0.82 ALK (0.56) ALKSTK4STK3STK26STK24
SCHEMBL1072921 0.82 ALK (0.54) ALKSTK4STK3STK26STK24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 — — US claimed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 — — US claimed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 — — US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 — — US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 — — US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 — — US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK ALK 3/4885CCKBR 1736/4885MAPT 3239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.